2.54

3.25% 0.08

After Hours: 2.54

Cardiff Oncology Inc (CRDF)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cardiff Oncology Inc stock is traded at $2.54, with a volume of 640.64K. It is up +3.25% in the last 24 hours and down -10.25% over the past month. Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Previous Close:

$2.46

Open:

$2.47

24h Volume:

640.64K

Relative Volume:

0.91

Market Cap:

$128.86M

Revenue:

$488.00K

Net Income/Loss:

$-41.44M

P/E Ratio:

-2.8222

EPS:

-0.9

Net Cash Flow:

$-31.47M

1W Performance:

+0.40%

1M Performance:

-10.25%

6M Performance:

-26.16%

1Y Performance:

+115.25%

1-Day Range:

$2.44

$2.54

1-Week Range:

$2.375

$2.63

52-Week Range:

$1.1704

$6.42

Cardiff Oncology Inc Stock (CRDF) Company Profile

Name

Cardiff Oncology Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

858-952-7570

Address

11055 FLINTKOTE AVENUE, SAN DIEGO, CA

Employee

Twitter

@cardiffoncology

Next Earnings Date

2024-10-31

Latest SEC Filings

CRDF's Discussions on Twitter

Compare CRDF with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRDF Cardiff Oncology Inc	2.54	128.86M	488.00K	-41.44M	-31.47M	-0.90
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-06-24	Initiated	Craig Hallum	Buy
Jan-05-22	Initiated	William Blair	Outperform
Dec-08-21	Initiated	Robert W. Baird	Outperform
Aug-09-21	Resumed	Maxim Group	Buy
Oct-22-20	Initiated	H.C. Wainwright	Buy
Oct-08-20	Initiated	Piper Sandler	Overweight

View All

Cardiff Oncology Inc Stock (CRDF) Latest News

Nov 20, 2024

Cardiff Oncology secures patent for cancer drug combo - Investing.com India

Nov 20, 2024

Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC - GlobeNewswire

Nov 20, 2024

Nov 19, 2024

CRDFCardiff Oncology, Inc. Latest Stock News & Market Updates - StockTitan

Nov 19, 2024

Cardiff Oncology secures patent for cancer drug combo By Investing.com - Investing.com UK

Nov 19, 2024

Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS ... - News-Press Now

Nov 19, 2024

Cardiff Oncology Secures Patent for Cancer Drug Combo Through 2043 | CRDF Stock News - StockTitan

Nov 19, 2024

Nov 12, 2024

Cardiff Oncology: Q3 Earnings Snapshot - AOL

Nov 12, 2024

Nov 09, 2024

HC Wainwright Has Lowered Expectations for Cardiff Oncology (NASDAQ:CRDF) Stock Price - MarketBeat

Nov 09, 2024

Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

Cardiff Oncology Reports Positive Q3 2024 Results and Clinical Progress - TipRanks

Nov 08, 2024

Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 08, 2024

Nov 07, 2024

Cardiff Oncology Reports 7.7x Better Results in Phase 2 Cancer Trial, $57.7M Cash Position | CRDF Stock News - StockTitan

Nov 07, 2024

Cardiff Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next - Seeking Alpha

Nov 07, 2024

Nov 03, 2024

Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Nov 03, 2024

Head to Head Review: Curis (NASDAQ:CRIS) versus Cardiff Oncology (NASDAQ:CRDF) - Defense World

Nov 03, 2024

Nov 02, 2024

Cardiff Oncology (FRA:XE7C) Float Percentage Of Total Shares Outstanding : 97.27% (As of Nov. 02, 2024) - GuruFocus.com

Nov 02, 2024

Nov 01, 2024

Cardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Up 7.2% in October - MarketBeat

Nov 01, 2024

Oct 30, 2024

Cardiff Oncology Announces Journal of Clinical Oncology - GlobeNewswire

Oct 30, 2024

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC - StockTitan

Oct 30, 2024

Oct 29, 2024

Alley Investment Management Company LLC Purchases New Stake in NVIDIA Co. (NASDAQ:NVDA) - Defense World

Oct 29, 2024

Oct 25, 2024

NA Liquid Biopsy Market 2024 To Witness Amazing Growth By 2032 - openPR

Oct 25, 2024

Oct 24, 2024

3 US Penny Stocks With Market Caps Over $40M - Simply Wall St

Oct 24, 2024

Oct 22, 2024

JAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 50+ Companies Working in the Domain - The Malaysian Reserve

Oct 22, 2024

Oct 15, 2024

KRAS Inhibitors Market Poised to Reach $157.6 Million by 2031, Driven by 5.61% CAGR As Revealed In New Report - WhaTech

Oct 15, 2024

Oct 14, 2024

Will Cardiff Oncology's Onvansertib Data Boost Its Stock Price? - RTTNews

Oct 14, 2024

Oct 10, 2024

Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve

Oct 10, 2024

Cardiff Oncology Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle

Oct 10, 2024

Oct 09, 2024